feed,title,long_url,short_url
Benzinga,"MorphoSys Discontinues US Discovery Activities, Takes â‚¬231M Impairment Charge",https://benzinga.com/general/biotech/22/03/26086387/morphosys-discontinues-us-discovery-activities-takes-231m-impairment-charge,https://bit.ly/3pUk8GI
Benzinga,JPMorgan Sees 'Limited Upside Potential' In Kymera Therapeutics' KT-474,https://benzinga.com/general/biotech/22/03/26085988/jpmorgan-sees-limited-upside-potential-in-kymera-therapeutics-kt-474,https://bit.ly/3pUJ9BI
